WeVote
Log In

Bill

Bill

HB 4533

Relating to the reimbursement of prescription drugs under Medicaid and the child health plan program.

89th Legislature (2025) Introduced by Tom Oliverson

HB 4533 restructures Medicaid and CHIP prescription drug reimbursement rates in Texas, affecting pharmacy payments and medication access for 4.5+ million low-income residents.

Referred to Human Services
#health&humanservicescommission(v0177) #health--children'sinsurance(i0388) #humanservices--childservices(i0895) #humanservices--medicalassistance(i0905) #medicaid(s4885) #medicine&prescriptiondrugs(s7338) #pharmacies&pharmacists(s1192) #pharmacybenefitmanagers(s0648)
0
WeVote Research Nonpartisan
Bill Summary · HB 4533

Legislative bill overview

HB 4533 modifies how Texas Medicaid and the Child Health Plan Program (CHIP) reimburse pharmacies for prescription drugs. The bill specifically addresses reimbursement methodologies, pricing benchmarks, or payment structures for pharmaceutical services under these state health programs. While the full text details are limited in the provided information, the bill represents a substantive change to drug payment policy affecting both state budgets and pharmacy operations.

Why is this important

Medicaid and CHIP serve approximately 4.5 million low-income Texans, making pharmacy reimbursement rates directly consequential for medication access and affordability. Changes to reimbursement formulas can either improve medication access by incentivizing pharmacy participation or create financial strain that reduces service availability in underserved areas. This bill also carries significant budget implications, as pharmaceutical costs represent a substantial portion of state health spending.

Potential points of contention

  • Pharmacy profitability and participation — Reimbursement cuts could reduce pharmacy willingness to serve Medicaid/CHIP patients, particularly in rural areas, potentially limiting access to medications
  • Drug cost control vs. service availability — Aggressive cost-containment measures may lower state expenses but could compromise medication availability or pharmacy viability
  • Manufacturer pricing negotiations — The bill may affect how Texas negotiates drug prices or leverage against pharmaceutical manufacturers, with implications for both costs and drug availability

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.